Associated Banc-Corp’s TG Therapeutics TGTX Stock Holding History

Associated Banc-Corp’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-33	Closed	-$2K	–	819
2020 Q4	$2K	Buy	+33	New	+$1.11K	﹤0.01%	847

Other funds holding TGTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Associated Banc-Corp's TGTX Position: Q1 2021 in Review

Associated Banc-Corp sold out of TG Therapeutics (TGTX) in Q1 2021, closing a stake of 33 shares — an estimated $2K sold.

Associated Banc-Corp first reported a position in TGTX in Q4 2020 and held it in 1 quarter. The position peaked at $2K in Q4 2020. 240 funds tracked by Wall St. Rank hold TGTX as of Q1 2021.

Associated Banc-Corp reported no remaining TG Therapeutics position as of Q1 2021 after selling out during the quarter.
Associated Banc-Corp sold 33 TG Therapeutics shares in Q1 2021, an estimated $2K.
Associated Banc-Corp first reported a position in TG Therapeutics in Q4 2020 and held it in 1 quarter.
Associated Banc-Corp's TG Therapeutics position peaked at $2K in Q4 2020.
240 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2021.

Based on Associated Banc-Corp's 13F filing for Q1 2021, filed 5 May 2021.